About Dr. Andrew Tobin
Andrew Tobin studied Biochemistry at Queen Mary College, the University of London, obtaining first-class honors before studying for a D.Phil at the University of Oxford. Following a post-doctoral period at Bristol Myers Squibb in Princeton, USA, Andrew returned to the UK to establish his laboratory at the University of Leicester. Funded through three consecutive Wellcome Trust Senior Research Fellowships, Andrew established a reputation in the field of receptor signaling.
Now at the University of Glasgow, his primary research interests focus on the rational design of novel drugs to treat the three global health challenges of dementia, asthma, and malaria. In this, Andrew runs a research laboratory of around 15 staff supported by basic research grants investigating aspects of disease biology and the action of drugs in the context of disease. The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd, a biotechnology company co-founded by Andrew with series A funding from the European Union.
Andrew is also the Director of the Advanced Research Centre (ARC), a collaborative initiative at the University of Glasgow underpinned by a £118M new build that will house over 550 researchers designed to drive interdisciplinary research.
Dr. Andrew Tobin on the web
Listen and subscribe
